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Abstract
Background: Compound targeting histone deacetylase (HDAC) represents a new era in molecular cancer therapeutics.
However, effective HDAC inhibitors for the treatment of solid tumors remain to be developed.
Methodology/Principal Findings: Here, we propose a novel HDAC inhibitor, N-Hydroxy-4-(4-phenylbutyryl-amino)
benzamide (HTPB), as a potential chemotherapeutic drug for solid tumors. The HDAC inhibition of HTPB was confirmed
using HDAC activity assay. The antiproliferative and anti-migratory mechanisms of HTPB were investigated by cell
proliferation, flow cytometry, DNA ladder, caspase activity, Rho activity, F-actin polymerization, and gelatin-zymography for
matrix metalloproteinases (MMPs). Mice with tumor xenograft and experimental metastasis model were used to evaluate
effects on tumor growth and metastasis. Our results indicated that HTPB was a pan-HDAC inhibitor in suppressing cell
viability specifically of lung cancer cells but not of the normal lung cells. Upon HTPB treatment, cell cycle arrest was induced
and subsequently led to mitochondria-mediated apoptosis. HTPB disrupted F-actin dynamics via downregulating RhoA
activity. Moreover, HTPB inhibited activity of MMP2 and MMP9, reduced integrin-b1/focal adhesion complex formation and
decreased pericellular poly-fibronectin assemblies. Finally, intraperitoneal injection or oral administration of HTPB efficiently
inhibited A549 xenograft tumor growth in vivo without side effects. HTPB delayed lung metastasis of 4T1 mouse breast
cancer cells. Acetylation of histone and non-histone proteins, induction of apoptotic-related proteins and de-
phosphorylation of focal adhesion kinase were confirmed in treated mice.
Conclusions/Significance: These results suggested that intrinsic apoptotic pathway may involve in anti-tumor growth
effects of HTPB in lung cancer cells. HTPB significantly suppresses tumor metastasis partly through inhibition of integrin-b1/
FAK/MMP/RhoA/F-actin pathways. We have provided convincing preclinical evidence that HTPB is a potent HDAC targeted
inhibitor and is thus a promising candidate for lung cancer chemotherapy.
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Introduction
The development of molecular-targeted therapies represents a
new era in cancer treatment [1]. Molecular-targeted drugs
specifically against cancer cells without affecting normal cells are
being developed [2–4]. Many of the molecular-targeted drugs are
inhibitors of proteins involved in signaling transduction, such as
growth factors, growth factor receptors or kinases [2,5].
Recent findings of overexpression and/or increased activity of
histone deacetylases (HDACs) in cancer cells and low basal level in
normal cells make HDACs potential therapeutic targets for cancer
treatment [6–8]. HDACs catalyze the removal of acetyl-groups
from lysine residues in the N-terminal tails of histones, leading to
chromatin condensation and transcriptional repression. In addition
to histones, HDACs have many other substrates involved in the
regulation of cellular function, such as p53, p21, HSP90, tubulin,
and of various transcription factors [9]. It has been demonstrated
that inhibition of HDACs reverses aberrant epigenetic status and
exhibits potent antitumor activities by inducing cell cycle arrest,
differentiation and/or apoptosis in diverse cancer cells [10,11].
To date, more than 15 HDAC inhibitors have been tested in
clinical trials in several hematological malignancies and solid
tumors [12]. These HDAC inhibitors include the short chain fatty
acids such as phenylbutyrate, butyrate, and valproic acid; the
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acids such as Trichostatin A (TSA), LAQ-824, and pyroxamide;
the cyclic peptides such as FK-228. Specifically, the U.S. Food and
Drug Administration has approved two HDAC inhibitors,
vorinostat (SAHA, suberoylanilide hydroxamic acid, ZolinzaH)
and romidepsin (FK228, depsipeptide, IstodaxH), for the treatment
of cutaneous manifestations of cutaneous T-cell lymphoma [15].
However, some adverse events occurred in patients treated with
vorinostat or other HDAC inhibitors, which may have resulted
from the high dose of inhibitors used during the treatment for solid
tumors in clinical trials [8,16].
The structures of HDAC inhibitors such as TSA and SAHA
could be divided into three motifs: a zinc-chelating motif
(hydroxamate), a linker consisting an aliphatic chain, and a polar
cap group. We have previously developed an HDAC inhibitor, N-
Hydroxy-4-(4-phenylbutyryl-amino)benzamide (HTPB), which
has been optimized for HDAC inhibition by structure-based
analyses [17]. In the present study, the antitumor and antimeta-
static activities of HTPB and the underlying mechanisms were
studied in lung cancer cell and animal models. The goal was to
develop an HDAC inhibitor with low IC50 to treat solid tumor
without significant side effects in preclinical models.
Results
HTPB is a pan-HDAC inhibitor and exhibits cancer cell-
specific cytotoxicity by promoting acetylation of various
proteins
The structure of HTPB and SAHA are shown in Fig. 1A (upper
panel). The cytotoxicity of HTPB was assessed in the IMR90
normal lung cell line and two human lung cancer cell lines including
A549 and H1299. SAHA was included as a positive control HDAC
inhibitor. HTPB induced significant cytotoxicity in A549 and
H1299 lung cancer cell lines with extrapolated IC50 value of
1.59 mM for A549 and 2.19 mM for H1299 (1.2–2.1 times more
potency than SAHA; IC50: A549=1.89 mM, H1299=4.59 mM),
without showing apparent cytotoxicity towards IMR90 normal lung
cell line (Fig. 1A, lower panel).
To examine the target specificity of HTPB, in vitro HDAC
inhibition assay was performed with class I, II, and IV HDACs. As
Figure 1. Effect of HTPB on cell viability and on the biomarkers associated with broad inhibition on numerous HDACs. (A) Chemical
structure of HTPB (upper left). Dose-dependent effects of HTPB on cell viability in IMR90, H1299, and A549 cells (lower left). Cells were treated with
0.5–10 mM of HTPB for 48 hours, and cell viability was assessed by MTT assay. A known HDAC inhibitor, SAHA, was used for comparison. (B) HTPB
suppressed activities of class I (HDAC1 and HDAC8), class II (HDAC4 and HDAC6), and class IV (HDAC11) HDACs in A549 cells. Data represent mean 6
SEM from three independent experiments. *** P,0.001. Dose-dependent effects (C) and time-dependent effects (D) of HTPB on the histone and non-
histone proteins. SAHA was included for comparison. (E) HTPB induced acetylation of histone H3 and H4 without affecting the total protein levels of
HDAC1 and HDAC 6. In addition, HTPB induced p21 protein expression in both A549 (p53 wild-type) and H1299 (p53 null) cells. The immunoblots
shown are representatives of three independent experiments.
doi:10.1371/journal.pone.0030240.g001
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isotypes including class I (HDAC1 and HDAC8), class II (HDAC4
and HDAC6), and class IV (HDAC11) were significantly inhibited
by HTPB. The biomarkers of HDAC inhibition are acetylation of
histone and non-histone proteins [11,18]. Exposure to HTPB
induced acetylation of histone H3, histone H4, p53 and tubulin in
a time- and dose-dependent manner (Fig. 1C & 1D), while it did
not affect the HDAC1 and HDAC6 protein levels (Fig. 1E).
Notably, HTPB was more potent than SAHA for induction of
tubulin acetylation (Fig. 1D). Despite the p53 status, HTPB
induced the expression of p21
Cip1 protein in A549 (p53 wild-type)
and H1299 (p53 null) cells (Fig. 1E), suggesting that activation of
p21
Cip1 involved changes in promoter-associated proteins, includ-
ing HDACs, not via p53-dependent transcriptional activation.
These results suggested that HTPB is a pan-HDAC inhibitor and
induces acetylation of histone and non-histone proteins.
HTPB induces cell cycle arrest and mitochondrial-
mediated apoptosis
To investigate the underlying mechanism of cell growth
repression by HTPB, the effects of HTPB on cell cycle progression
in A549 and H1299 cells were assessed by flow cytometry.
Treatment with 5 mM HTPB caused cell accumulation at G2/M
phase and apoptosis (sub-G1) in both cells and an additional G1
arrest in H1299 cells at 48 hours treatment (Fig. 2A), indicating
that HTPB exerted a cell cycle deregulation effect.
To further elucidate the HTPB-induced apoptosis, we
performed a DNA ladder analysis and found that ladders
appeared in A549 and H1299 cells after HTPB treatments
(Fig. 2B). Moreover, treatment with 5 mM HTPB caused a time-
dependent increase in pro-apoptotic protein, Bad and Bak, while
it decreased the anti-apoptotic protein Bcl-2 and Bcl-XL (Fig. 2C).
HTPB treatment significantly stimulated caspase-3 and caspase-
9 (an indicator of the intrinsic mitochondrial pathway) activities
after 24 hours treatment whereas the activity of caspase-8 (an
indicator of the extrinsic membrane receptor pathway) remained
unaffected in both cells lines tested (Fig. 2D). The cleavage of
pro-caspase-9 and -3 was also seen after HTPB treatment (Fig.
S1). These results suggested that intrinsic apoptotic pathway
may play a role in HTPB-induced cytotoxicity in lung cancer
cells.
HTPB at non-cytotoxic doses suppresses migration ability
in lung cancer cell lines via inhibiting activity of integrin-
b1/FAK/MMP/RhoA/F-actin motility control
To investigate whether HTPB inhibited cell migration in A549
and H1299 lung cancer cell lines, trans-well migration assay and
wound-healing assay were performed at non-cytotoxic doses. As
shown in Fig. 3A and 3B, the percentage and distance of migrated
cells were significantly reduced after HTPB treatment. These
results suggested that HTPB significantly inhibited lung cancer cell
migration at non-cytotoxic doses.
Figure 2. HTPB induces cell cycle arrest and apoptosis. (A) The effects of HTPB on cell cycle distribution in A549 and H1299 cells. Cells were
treated with 5 mM HTPB for indicated times and assessed by flow cytometry. The percentage of G2/M and sub-G1 fraction population is plotted in the
histogram. G2/M arrest and sub-G1 induction are indicated by arrows. (B) HTPB caused apoptotic DNA ladders in A549 and H1299 cells treated with
5 mM HTPB for 48 hours. HTPB induced intrinsic apoptosis. Cells were treated with 5 mM HTPB for indicated times and cell lysates were subjected to
Western blot analyses (C) and caspase activity assay (D). Pro-apoptotic proteins Bad and Bak were up-regulated and anti-apoptotic proteins Bcl-2 and
Bcl-XL were down-regulated. Caspases-3 and -9 were up-regulated in both A549 and H1299 cells. Data represent mean 6 SEM from three
independent experiments. * P,0.05; ** P,0.01.
doi:10.1371/journal.pone.0030240.g002
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inhibition, enzyme activities of matrix metalloproteinases MMP-2
and MMP-9 were examined by substrate-specific gelatin-zymography
assay. The data indicated that MMP-2 and MMP-9 enzyme activities
were significantly decreased in A549 and H1299 cells treated with
HTPB for 48 hours (Fig. 3C). In addition, HTPB markedly decreased
RhoA activity in lung cancer cells (Fig. 3C). To determine whether
focal adhesion complex played a role in HTPB-inhibited cancer cell
migration, we examined the activities of focal adhesion kinase (FAK)
and integrin-b1 after HTPB treatment. Asshown in Fig.3D,the levels
of integrin-b1 and phospho-FAK were significantly reduced in a dose-
dependent manner in 48 hours after HTPB treatment. In addition, F-
a c t i nd y n a m i c sa sd e t e c t e db yc o n f o c a li m m u n o f l u o r e s c e n c e
microscopy illustrated that the polymerization of F-actin was
dramatically inhibited after HTPB treatment in H1299 and A549
cells (Fig. 3E). These results suggested that HTPB decreased
migratory activities of lung cancer cells partly through inhibiting the
activities of MMPs and RhoA protein and disrupting focal adhesion
complex and F-actin cytoskeleton arrangement.
HTPB inhibits lung tumor xenograft growth in vivo
without significant side effects
To further evaluate the antitumoractivity of HTPB, Balb/c nude
mice bearing A549 lung tumor xenograft were injected intraper-
itoneally or orally with 25–100 mg/kg of HTPB, 3 days/week for
three weeks. As shown in Fig. 4A and Fig. S2A, intraperitoneal
treatment with 25 and 50 mg/kg HTPB significantly inhibited
tumor growth by 80% and 94%, compared with DMSO control,
while 50 mg/kg SAHA inhibited tumor growth only by 65% (left
panel). Oral administration with 50 and 100 mg/kg HTPB
significantly inhibited tumor growth by 39% and 79% (right panel)
respectively. In addition, significantly less tumor weight was
observed in mice treated by HTPB intraperitoneally (Fig. 4B, left
panel)ororally(rightpanel)than incontrolmice. Note that the anti-
tumor growth effect of HTPB was 2–4 times more potent than
SAHA as assessed by tumor weight (Fig. 4B, left panel). Treatment
with HTPB did not adversely affect body weight (Fig. 4C and Fig.
S2B) and caused no detectable toxicity as examined by hematolog-
ical biochemistry examinations (Fig. 4D).
Figure 3. HTPB inhibits cancer cell migration via reduced activities of matrix metalloproteinases, RhoA, and focal adhesion
complex. (A) The image from trans-well migration assay and (B) wound-healing assay indicated that after 48 hours treatment at non-cytotoxic
doses, HTPB inhibited migratory activity in a dose-dependent manner. * P,0.05; ** P,0.01; scale bars: 400 mm. (C) Gelatin-zymography assay and
RhoA-GTP GST pull-down assay showed that MMP-2 and MMP-9 enzyme activities were suppressed and RhoA-GTP expression was reduced in A549
and H1299 cells after 2.5 mM HTPB treatment for 48 hours. (D) Expression of integrin-b1 and phosphorylation of FAK at Tyr-397 were down-regulated
in H1299 and A549 cells after HTPB treatment for 48 hours at the indicated doses. (E) HTPB led to F-actin dysregulation by immunofluorescence
analyses. Cells were treated with 5 mM HTPB for 48 hours, and then fixed and stained with phalloidin (F-actin). Scale bars: 40 mm.
doi:10.1371/journal.pone.0030240.g003
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To explore the anti-metastasis activity of HTPB, highly
metastatic 4T1-luc breast cancer cells were treated with
1.92 mM HTPB for 48 hours. Such a treatment did not change
cell viability (Fig. 5A and Fig. S3A) or cell cycle distribution (Fig.
S3B) of 4T1-luc breast cancer cells but it decreased transwell
migration capacities to 50% compared to the un-treated control
(Fig. S3C). Interestingly, pericellular poly-fibronectin assemblies
were decreased in 4T1-luc cells after HTPB treatment (Fig. 5B).
The treated cells were then injected intravenously via tail vein into
Balb/c mice and photographed by IVIS-50 imaging system at
day-1, 4, 7, and 13 to observe in vivo cancer cell metastasis after
Figure 4. HTPB effectively inhibits A549 xenograft growth without significant side effects. (A) Balb/c nude mice bearing the established
A549 tumors (,50 mm
3) were treated with HTPB via intraperitoneal (left panel) or oral administration (right panel) for three weeks (3 days/week). A
known HDAC inhibitor, SAHA, was used for comparison in intraperitoneal experiments. The tumor volumes of mice were measured twice weekly.
Points, mean; bars, 6SEM. Three mice per group for intraperitoneal injection and five mice per group for oral treatment were used in the xenograft
experiment. (B) The tumor weights of mice were measured. P values were for comparisons with DMSO or vehicle control (* P,0.05, ** P,0.01).
(C) HTPB treatments did not cause significant body weight loss of tested animals. (D) Hematological biochemistry tests including GOT, GPT, albumin
and creatinine were examined and the results showed no significant differences between HTPB treatment and DMSO or solvent control.
doi:10.1371/journal.pone.0030240.g004
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significantly delayed lung metastasis of 4T1-luc cells (right panel),
compared to DMSO control (left panel). These results suggested
that HTPB inhibited metastasis of 4T1-luc cells in vivo.
HTPB induces protein acetylation, apoptosis and FAK
inhibition in vivo
To confirm that HTPB suppressed tumor growth and tumor
metastasis via targeting the HDACs, inducing apoptosis and
inhibiting FAK in vivo, mice bearing established A549 tumors were
treated with a single dose of HTPB at 50 mg/kg. After treatment,
tumors were dissected and cell lysates were subjected to Western blot
or immunohistochemistry analysis. Acetylation of histone H3, histone
H4 and p53 were profoundly increased after 2 hours treatment in
tumor xenograftcollected. The protein levels of anti-apoptoticBcl-XL
started to decrease after 2 hours treatment (Fig. 6A), while the level of
cleaved caspase-3 protein was increased in tumor xenograft collected
on day 25 (Fig. 6B, upper panel). Activated phosopho-FAK and
phosopho-AKT were also decreased in HTPB-treated tumor
xenograft (Fig. 6B, middle and lower panels). These results
demonstrated that HTPB could induce apoptosis and down-regulate
migration regulators, FAK and AKT, in vivo.I na d d i t i o n ,i n c r e a s eo f
HDAC inhibition biomarkers such as acetylation of histone H3,
histone H4 and p53 was evident in tumors of treated mice.
Figure 5. HTPB delays lung metastasis of 4T1-luc breast cancer cell in animal models. (A) 4T1-luc mouse breast cancer cells were treated
with 1.92 mM HTPB for 48 hours. HTPB did not significantly affect cell growth of 4T1-luc cells during the indicated treatments. (B) Fibronectin
assembly on the surface of 4T1-luc cells measured by immunofluorescence analyses showed that HTPB treatment reduced pericellular poly-
fibronectin assemblies. (C) The treated 4T1-luc cells were injected intravenously via tail vein into Balb/c mice and observed for the luciferase signals
and photographed using IVIS50 for 13 days after drug treatment. HTPB significantly delayed lung metastasis.
doi:10.1371/journal.pone.0030240.g005
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Since HDACs are promising targets for cancer therapy, a
number of HDAC inhibitors are in clinical trials as single agent
and/or in combination with other anticancer drugs [10]. However,
none have yet been demonstrated to be effective as treatment for
solid tumors. Here, we provide compelling evidence from cell and
animal studies that HTPB, a phenylbutyrate-based compound, is a
potential HDAC inhibitor for lung cancer treatment. HTPB
targeted numerous members within three classes of HDACs in vitro
and efficiently stimulated protein acetylation in cell and animal
models (Fig. 1 and 6). HTPB repressed cell viability and induced
apoptosis in lung cancer cell lines (Fig. 1 and 2). In addition, HTPB
reduced cell migration at non-cytotoxic dose via inhibition of Rho/
F-actin and integrin-b1/FAK/MMP pathways (Fig. 3). The
xenograft experiments further confirmed that HTPB induced cell
apoptosis and thereby inhibited tumor growth in vivo without
adversely affecting body weight and hematological parameters
(Fig. 4 and 6). In addition, HTPB significantly inhibited lung
metastasis in vivo through inhibition of pericellular poly-fibronectin
assemblies at non-cytotoxic concentrations (Fig. 5 and 6).
Collectively, these results suggested that HTPB is a promising
candidate HDAC inhibitor for lung cancer treatment.
We provide the first evidence that HTPB significantly inhibited
tumor growth by both intraperitoneal and oral administrations in
animal model (Fig. 4). The anti-tumor growth effect could be
optimized if a better solvent was used during oral administration.
Upon HTPB treatment, G2/M arrest were induced and
subsequently led to mitochondria-mediated apoptosis (Fig. 2).
The G1 arrest observed in H1299 cells could be due to the
induced expression of p21
Cip1 after HTPB treatment (Fig. 1E).
p21
Cip1 is a cyclin-dependent kinase inhibitor and has been shown
to mediate G1 cell cycle arrest [19]. Our results (Fig. 2 and 6)
showed that treatment of HTPB resulted in a time-dependent
reduction in the levels of the anti-apoptotic proteins Bcl-2 and
Figure 6. HTPB effectively induced protein acetylation, apoptosis and pFAK/pAKT inactivation in vivo. (A) Mice bearing established
(about 100,200 mm
3) A549 tumors were injected intraperitoneally with a single dose of HTPB at 50 mg/kg. After treatment for the indicated time,
tumors from two representative mice of each time point (a–f) were harvested and subjected to Western blot using anti-actyl-histone H3, H4 and p53
and Bcl-XL antibodies. (B) Immunohistochemistry analyses were performed using antibody against cleaved-form of caspase-3, p-FAK and p-AKT
(brownish color). Original magnification6200.
doi:10.1371/journal.pone.0030240.g006
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Bak was increased. The Bcl-2 family of proteins constitutes a
critical mediator in the mitochondrial pathway of apoptosis [20].
Furthermore, the progression of apoptosis involves the activation
of a cascade of proteases called caspases. Theoretically, the
extrinsic pathway is related to the activation of caspase-8 and the
intrinsic pathway is associated with activation of caspase-9. Both
pathways converge to a common pathway involving the activation
of caspase-3 [20,21]. As shown in our data, HTPB apparently
stimulated caspases-3, caspase-9 and to a lesser extent caspase-8
activities. Importantly, induced caspase-3 and reduced Bcl-XL
were confirmed in HTPB-treated tumor xenograft (Fig. 6). It is
noteworthy that we also found that HTPB caused induction of the
acetylated-p53 protein, which are highly expressed and correlated
with apoptosis induction [22]. Together, these results suggested
that HTPB induced the execution of apoptosis partly through the
activation of the intrinsic mitochondrial pathway. Experiments
using specific caspase inhibitors to test whether intrinsic apoptosis
accounted for HTPB-induced cell death are worthy of further
examinations.
We have also showed for the first time that HTPB significantly
delayed lung metastases in animal model (Fig. 5). Our cellular
data indicated that HTPB inhibited cancer cell migration
through inhibiting activity of matrix metalloproteinases, RhoA,
integrin-b1 and focal adhesion complex (Fig. 3) and disrupting F-
actin arrangement (Fig. 3). Activated integrins control down-
stream signaling pathway through non-receptor tyrosine kinase
FAK [23,24] which correlates with cancer metastasis [25].
Integrin-b1 has been genomically identified and shown to
clinically promote cancer metastasis [26]. In addition, the Rho/
Rac/CDC42 GTPase proteins, which are downstream effectors
of FAK, control cell motility through WASP and ARP2/3
complex signaling pathway to regulate the extension and
branching of actin filament and cell protrusion [27]. We
confirmed that HTPB treatment decreased integrin-b1, p-
FAK(Y397) and decreased the activities of RhoA and matrix
metalloproteases, MMP-2 and MMP-9. Importantly, reduced p-
FAK(Y397) and its downstream effector p-AKT were confirmed
in HTPB-treated tumor xenograft (Fig. 6). Note that integrin-b1
downstream signaling players RhoA is known to regulate the
actin stress fiber-coordinated fibronectin matrix assembly [28],
which is associated with cancer colonization and metastasis in the
lungs [29]. Our study also confirmed the inhibition of pericellular
poly-fibronectin assembly by HTPB treatment (Fig. 5). The
question remained is whether the anti-motility effect of HTPB is
due to HDAC inhibition. Our previous study on another HDAC
inhibitor, OSU-HDAC-44 showed that OSU-HDAC-44 de-
creased the activity of RhoA via induction of srGAP1 and
contributed to dysregulation of F-actin dynamics [30]. The
srGAP1 gene, which encodes a GTPase activating protein known
to regulate axon guidance [31], was confirmed to be in the open
chromatin structure and increased in expression level in our
previous study [30]. HTPB may inhibit cancer cell motility partly
through reactivation of srGAP1 via promoting histone acetylation
of srGAP1 promoter and further attenuation of downstream Rho/
FAK/MMP signaling pathway. Note that TSA has been shown
to up-regulate RECK via transcriptional activation to inhibit
MMP activity in human lung cancer cells [32]. Whether other
Rho family of GTPases, such as Rac and Cdc42 and other
metastasis-related proteins such as RECK, WASP and ARP2/3
complex are involved in HTPB-induced migration inhibition is
worth further investigation.
In conclusion, our findings show that HTPB is a novel pan-
HDAC inhibitor that exhibits antitumor and antimetastatic
activities in lung cancer cells but not in normal lung cells in cell
and xenograft models, which involves not only histone acetylation-
dependent activation of gene transcription, but also activation of
intrinsic apoptotic pathways and down-regulation of integrin-b1/
FAK/MMP/RhoA/F-actin motility control pathway. Note that
HTPB induced stronger cytotoxicity in lung cancer cells and had
greater inhibitory effect on tumor growth in lung tumor xenografts
than SAHA. In addition, HTPB inhibited the invasion of lung
cancer cells at a lower dose than SAHA did [33]. A better efficacy
in vivo of HTPB over SAHA may be due to longer retention time of
HTPB than SAHA in animal. Pharmacokinetics and pharmaco-
dynamics studies for both SAHA and HTPB are under the
investigations. Furthermore, HTPB showed significant inhibition
of in vitro HDAC activity compared to MS275 (Fig. S5), a class I
HDAC inhibitor with preference for HDAC1. In comparison with
our previous HDAC inhibitor, OSU-HDAC-44, the synthesis of
HTPB is easier (only 2 steps, but 3 steps for HDAC-44) and with
higher yield. Methyl groups at a-position of HDAC-44 were
removed to form the HTPB in order to minimize the bulkiness and
steric hindrance of amide linkage. The IC50 values of HTPB in
various lung cancer cells were close to OSU-HDAC-44 [30]. In
addition, HTPB significantly inhibited lung metastasis in vivo at
non-cytotoxic concentrations. These anti-metastasis data in vitro
and in vivo were not shown for OSU-HDAC-44. It is worthy to
investigate whether there is selective chromatin change in a
fraction of gene loci by genome-wide chromatin immunoprecip-
itation-on-chip assay. Collectively, our data provide compelling
evidence that HTPB is an HDAC inhibitor and could be tested for
lung cancer treatment and combination chemotherapy.
Materials and Methods
Ethics Statement
All animals were obtained from the National Laboratory
Animal Center (Republic of China, Taiwan) with the approval
of Institutional Animal Care and Use Committee (IACUC),
National Cheng Kung University (IACUC Approval No. 99131)
and were maintained in pathogen free conditions. The study
approval by the review board institution and ethics committee was
confirmed by National Cheng Kung University.
Cell lines and culture conditions
Human normal lung cell line IMR90 and human lung cancer
cell lines, A549 and H1299, were obtained from the American
Type Culture Collection (ATCC, Manassas, VA). Luciferase
expressing murine breast cancer cell line, 4T1-Luc, was obtained
from Dr. M.L.Kuo (Institute of Toxicology, National Taiwan
University, Taipei, Taiwan). All cell lines were cultured in
Dulbecco’s Modified Eagle’s Medium (GIBCO, Grand Island,
NY) containing 10% fetal bovine serum (FBS) (BIOCHROM AG,
Leonorenstr, Berlin, Germany) and 1% penicillin-streptomycin
(GIBCO), and incubated at 37uCi n5 %C O 2 atmosphere.
Preparation of HTPB
Synthesis of N-hydroxy-4-(4-phenylbutanamido)-benzamide 2
(HTPB) was successfully accomplished in two steps as shown in
Fig. S6. 4-(4-phenylbutanamido) benzoic acid 1 was prepared by
treatment of 4-phenylbutanoic acid with oxalyl chloride followed
by 4-amino benzoic acid. Standard peptide coupling reaction
between the resulting acid 1 and hydroxyl amine hydrochloride,
using PyBop as a coupling reagent and Et3N provided the
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To a stirred solution of 4-phenylbutanoic acid (328 mg,
2 mmol, 1 equiv) in anhydrous CH2Cl2 (5 ml) was added oxalyl
chloride (504 mg, 336 ml, 4 mmol, 2 equiv) at 0uC under N2. The
resulting mixture was warmed to ambient temperature. After
having been stirred for 4 hours, the reaction mixture was
concentrated in vacuo. The crude residue was co-evaporated with
anhydrous CH2Cl2 (265 ml) and dried in vacuo. The resulting acid
chloride residue was dissolved in anhydrous CH2Cl2 (5 ml) and 4-
amino benzoic acid (329 mg, 2.4 mmol, 1.2 equiv) was added at
0uC followed by Et3N (417 ml, 303 mg, 3 mmol, 1.5 equiv) under
N2. After having been stirred for 10 hours at ambient tempera-
ture, the reaction mixture was quenched with water (10 ml) and
then extracted with CH2Cl2 (2610 ml). The combined organic
layers were dried (MgSO4), filtered and concentrated under
reduced pressure. The crude residue was purified by column
chromatography (EtOAc/hexanes, 9/1) on silica gel to afford
498 mg of 4-(4-phenylbutanamido)benzoic acid 1 as a white solid:
1H NMR (DMSO-d6, 400 MHz) d12.65 (br s, 1H, COOH), 10.18
(s, 1H, NH), 7.87 (d, J=8.8 Hz, 2H), 7.70 (d, J=8.4 Hz, 2H),
7.31-7.16 (m, 5H), 2.63 (t, J=7.6 Hz, 2H), 2.36 (t, J=7.4 Hz,
2H), 1.90 (quin, J=7.6 Hz, 2H);
13C NMR (DMSO-d6,
100 MHz) d 171.9, 167.2, 143.4, 141.8, 130.5, 128.5, 126.0,
125.1, 118.5, 36.0, 34.7, 26.8; MS (ESI) Calculated for
C17H16NO3: 283, Found: 282 (M-H
+, 100); High-Resolution
MS (TOF -ESI) Calculated for C17H16NO3 (M-H
+): 282.1130,
Found: 282.1123; Rf 0.32 (EtOAc/hexanes, 9/1).
N-hydroxy-4-(4-phenyl-butyrylamino)-benzamide (2)
To a stirred solution of acid 1 (283 mg, 1 mmol, 1 equiv) in
DMF (1 mL) was added triethyl amine (121 mg, 167 mL,
1.2 mmol, 1.2 equiv) followed by PyBOP (624 mg, 1.2 mmol,
1.2 equiv) at 0uC. The Resulting reaction mixture was warmed at
ambient temperature. After having been stirred for 4 hours at
ambient temperature, the reaction mixture was cooled to 0uC and
hydroxylamine hydrochloride (138 mg, 2 mmol, 2 equiv) was
added followed by triethyl amine (151 mg, 209 ml, 1.5 mmol, 1.5
equiv) and the resulting mixture was stirred at ambient
temperature for overnight. The reaction mixture was then
quenched with water (5 ml) and extracted with EtOAc (365 ml).
The combined organic layers were washed with brine (10 ml),
dried (MgSO4), filtered and concentrated under reduced pressure.
The crude residue was purified by column chromatography
(EtOAc/hexanes, 9/1) on silica gel to afford 259 mg of N-
hydroxy-4-(4-phenylbutanamido)benzamide 2 as a white solid:
1H
NMR (DMSO-d6, 400 MHz) d 11.08 (s, 1H), 10.08 (s, 1H), 8.92 (s,
1H), 7.70 (d, J=8.8 Hz, 2H), 6.64 (d, J=8.4 Hz, 2H), 7.31-7.16
(m, 5H), 2.62 (t, J=7.4 Hz, 2H), 2.34 (t, J=7.4 Hz, 2H), 1.90
(quin, J=7.6 Hz, 2H);
13C NMR (DMSO-d6, 100 MHz) d 171.3,
163.9, 141.8, 141.6, 128.3, 128.3, 127.6, 126.9, 125.8, 118.3, 35.8,
34.6, 26.6; MS (ESI) Calculated for C17H18N2O3: 298, Found:
282 (M-H
+, 100); High-Resolution MS (TOF -ESI) Calculated for
C17H17N2O3 (M-H
+): 297.1239, Found: 297.1236; Rf 0.35
(EtOAc/hexanes, 9/1).
Cell cytotoxicity/MTT assay
Cells were seeded at 5610
4 cells/well in 12-well plates and
treated with various concentrations of HTPB or SAHA for
48 hours, followed by 0.5 mg/ml of 3-(4.5-dimethylthiazol-2-ly)-
2,5-diphenyl tetrazolium bromide (MTT, Sigma-Aldrich, St.
Louis, MO) for 30 minutes at 37uC in a 5% CO2 humidified
incubator to determine their cytotoxic effects. Cell cytotoxicity was
expressed as percentage loss of cell viability compared with control
(DMSO), and 50% of inhibition concentration (IC50) of death cell
lines was calculated.
Cell cycle analysis
Cell cycle distribution was determined by flow cytometry. Cells
were treated with 5 mM HTPB for 24 or 48 hours, and then fixed
with 70% ethanol for at least 2 hours at 220uC. Fixed cells were
stained with a solution containing 20 mg/ml propidium iodide,
200 mg/ml RNase A, and 0.1% Triton X-100 for 20 minutes in
the dark. Cell cycle distribution was performed using FACScan
flow cytometry (BD Biosciences, Mountain View, CA) and cal-
culated with ModFIT LT 2.0 version software (BD Biosciences).
Determination of the apoptotic DNA ladder
Fixed cells were centrifuged, resuspended in 100 ml of DNA
extraction buffer (0.2 M Na2HPO4, 0.1 M citrate acid, and 0.5%
triton X-100, pH 7.8), and then incubated for 1 hour at 37uC.
After centrifugation, the supernatant was collected and incubated
with 5 ml RNase A (100 mg/ml) for 1 hour at 37uC, and followed
by digestion with 5 ml proteinase K (20 mg/ml) for 1 hour at
37uC. After electrophoresis, the gels were stained and imaged.
Caspase activity assay
Caspase activity was measured with the caspase luminescent
assay kit (Promega, Madison, WI) according to the manufacturer’s
instructions. Cells seeded in a 96-well plates were treated with
5 mM HTPB for 12 or 24 hours, followed by incubation with
various synthetic caspase substrates (Ac-DEVD-pNA, Ac-LETD-
pNA, and Ac-LEHD-pNA) to measure the activity of caspases-3,
-8, and -9, respectively. After incubation for an hour, luminescence
was detected using a SpectraMaxH M5 microplate reader
(Molecular Devices, Sunnyvale, CA).
Western blot analysis
The cells were lysed on ice. Lysates were centrifuged at 13,000
r.p.m. for 15 min at 4uC, SDS gel loading buffer was added and
samples containing equal amounts of protein (50 mg) were
separated on a 10% SDS-PAGE then electro-blotted onto a
Immobilon-P membrane (Millipore Co., Bedford, MA) in transfer
buffer. Immunoblotting was performed for various proteins, using
the antibodies with conditions described in the Table S1.
HDAC inhibition Assay
Immunoprecipitation of different HDAC isotypes from nuclear
extract were performed using specific anti-HDAC-1, -4, -6, -8, and
-11 antibodies as described in the Table S1. The HDAC activity
assay was performed using a HDAC fluorescent activity assay kit
(BIOMOL Inc, Plymouth Meeting, PA) according to the
manufacturer’s instructions. Specific HDAC isotypes were added
to the diluted HTPB (1 or 2 mM), and then the substrate was
added. Samples were incubated for 10 min at 25uC then the
reaction was stopped by adding developer. After incubation for
10 min, luminescence was recorded with a SpectraMaxH M5
microplate reader (Molecular Devices, Sunnyvale, CA).
Trans-well migration assay
Cells (,2610
5) suspended in serum-free DMEM medium were
pretreated with DMSO control or HTPB, and placed in the upper
chamber of culture-insert. DMEM medium containing 10% FBS
was added to the lower chamber as chemoattractants and the cells
were incubated at 37uC for 12 hours. The cells attached on the
reverse side of the membrane were stained with crystal violet and
cells in 5,10 randomly selected fields were counted under
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independent experiments were performed.
Wound healing assay
Cancer cells were treated with different concentration of HTPB
or DMSO for 48 hours. A cell-free gap of 400 mm was created
after removing the Culture-Insert (Ibidi, Martinsried, Germany).
The cells that had migrated into the wound area were calculated
as 400 mm - (5–12 hours area6400 mm)/0 hour area. Three
independent experiments were photographed and quantified un-
der a microscope.
RhoA activation assay
The RhoA activation assay was performed using active Rho
pull-down and detection Kit (Pierce, Rockford, IL). A glutathione
S-transferase (GST) fusion protein containing the Rho binding
domain (RBD) from Rhotekin was used. One mg protein lysates
were incubated with 400 mg of purified GST-Rhotekin-RBD
immobilized on agarose-glutathione beads for 1 hour at 4uC with
constant agitation. The beads were washed three times with 16
Lysis/Wash buffer and bound proteins were eluted and subjected
to Western blot analysis using RhoA antibody as described in the
Table S1.
Gelatin-zymography assay
Conditioned medium were collected from cells treated with
DMSO or HTPB for 48 hours, and analyzed by gelatin
zymography in 0.1% gelatin-8% acrylamide gels. After electro-
phoresis, gels were washed with 2.5% Triton X-100 to remove
SDS and renature the MMP-2 and MMP-9 in the gel. Then the
gels were incubated in the developing buffer overnight to induce
gelatin lysis by renatured MMP-2 and MMP-9. The gel was then
stained with 0.5% Coomassie blue G for 1 hour. The proteolytic
activities were identified as clear bands.
Immunofluorescence staining and confocal microscopic
analysis
To stain for DNA and F-actin, the fixed cells were stained with
DAPI and Phalloidin as described in the Table S1, respectively, for
1 hour and then the images were recorded by an OLYMPUS
FV1000 confocal microscope (Olympus America Inc., Melville,
NY).
Animal model-in vivo anti-tumor growth assay
Athymic nu/nu mice (Balb/c), 4–5 weeks of age, were obtained
from the National Laboratory Animal Center (Republic of China,
Taiwan) with the approval of Institutional Animal Care and Use
Committee (IACUC), National Cheng Kung University (IACUC
Approval No. 99131) and were maintained in pathogen free
conditions. Mice were implanted subcutaneously with 5610
6
A549 cells in 0.1 ml Hanks’ balanced salt solution (HBSS) in one
flank per mouse. When tumors had attained a mass of ,50 mm
3,
the mice were treated intraperitoneally or orally with HTPB
(25 mg/kg, 50 mg/kg or 100 mg/kg), SAHA (50 mg/kg), DMSO
or oral solvent (0.5% methylcellulose and 0.1% Tween 80 in
ddH20) on days 1, 3, and 5 for three weeks. The tumor size was
measured according to the formula: (Length6Width
2)/2. Prior to
sacrifice, the animals were anesthetized and blood samples were
collected by intracardiac puncture for the hematological biochem-
istry tests. Tumor samples and mice organ tissues were resected,
fixed and embedded in paraffin for histologic examination. To
examine the biological effects of HDAC inhibition in tumors, mice
bearing established (about 100 mm
3) A549 tumors were treated
intraperitoneally with a single dose of HTPB at 50 mg/kg. After
treatment for indicated time, tumors were harvested and subjected
to Western blot or immunohistochemistry analyses.
Animal model-in vivo anti-tumor metastasis assay
The Balb/c mice were obtained and approved by Institutional
Animal Care as described above. Highly metastatic 4T1-luc
mouse breast adenocarcinoma cells were pre-treated with
1.92 mM HTPB or DMSO for 48 hours. Cells were then
trypsinized and recovered for 2 hours at 37uC in media containing
20% FBS with HTPB or DMSO. Cells (1610
5 cells/200 ml) were
subsequently resuspended in serum-free DMEM medium and
intravenously injected via tail vein into Balb/c mice. These mice
were then given 3 mg/mice endotoxin-free luciferase substrate
(VivoGlo
TM, Promega) and photographed using IVIS-50 imaging
system (XENOGEN) at day-2, 4, 8 and 13.
Tissue Western Blot and immunohistochemistry (IHC)
assay
Tumor tissues from mice were analyzed using IHC assay to
detect the expression levels of cleaved caspase-3, phospho-AKT
and phospho-FAK proteins as described in the Table S1. Tumor
tissues from mice were subjected to Western blot analysis for the
acetylated proteins and apoptotic related proteins.
Biochemistry and hematology tests
Whole blood samples of treated mice were collected by
intracardiac puncture and stored at 4uC in tube with or without
EDTA anticoagulant. Biochemistry evaluation included glutamate
oxaloacetate transaminase (GOT), glutamate pyruvate transami-
nase (GPT), albumin levels and creatinine levels. Hematology tests
included platelet count, red blood cell (RBC), and white blood cell
(WBC). All experiments and procedures were done in accordance
with the Institutional Care Use Committee guidelines.
Statistical analysis
The SPSS program (SPSS Inc. Headquarters Chicago, Illinois)
was used for all statistical analysis. Statistical analysis was
performed using Student’s t-test. Data shown were representatives
of at least three independent experiments. Data represent mean 6
SEM. P,0.05 was considered to be statistically significant.
Supporting Information
Figure S1 Caspase cleavage assay demonstrating the
induction of intrinsic apoptosis by HTPB. Cells were
treated with 5 mM HTPB for indicated times and then subjected to
Western blot analyses using anti-caspase-9 or anti-caspase-3
specific antibodies. The active cleaved forms of caspases are as
indicated.
(TIF)
Figure S2 HTPB effectively inhibits A549 xenograft
growth without significant causing significant body
weight loss of tested animals. (A) Balb/c nude mice bearing
the established A549 tumors (,50 mm
3) were treated with HTPB
via intraperitoneal for three weeks (3 days/week). A known HDAC
inhibitor, SAHA, was used for comparison in intraperitoneal
experiments. The tumor volumes of mice were measured twice
weekly. Six mice per group were used in the xenograft experiment.
Points, mean; bars, 6SEM. (* P,0.05, ** P,0.01) (B) HTPB
treatments did not cause significant body weight loss of tested
animals.
(TIF)
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and migration of 4T1-luc cells. (A) Highly metastatic 4T1-luc
breast cancer cells were treated with HTPB for 48 hours and cell
viability was assessed by MTT assay. (B) The cell cycle distribution
of treated 4T1-luc cells returned to the same distribution as
DMSO control at 5 mM treatment for 48 hours, though a
transient G1 arrest was observed for 24 hours. (C) 4T1-luc cells
treated with 1.92 mM HTPB for 48 hours decreased transwell
migration capacities to 50% compared to the un-treated control.
Data represent mean 6 SEM from three independent experi-
ments. P values are as indicated.
(TIF)
Figure S4 HTPB delays lung metastasis of 4T1-luc
breast cancer cell in animal models. The treated 4T1-luc
cells were injected intravenously via tail vein into Balb/c mice and
observed for the luciferase signals and photographed using IVIS50
for 13 days after drug treatment. HTPB significantly delayed lung
metastasis.
(TIF)
Figure S5 In vitro HDAC inhibition assays for HTPB
and MS275. The pan-HDAC inhibitor HTPB showed significant
inhibition of in vitro HDAC activity compared to MS275, a class I
HDAC inhibitor. A known pan-HDAC inhibitor, SAHA, was
used for comparison. Data represent mean 6 SEM from three
independent experiments. P values are as indicated.
(TIF)
Figure S6 Schematic presentation of 2-steps synthesis
of HTPB.
(TIF)
Table S1 The antibodies and their reaction conditions
used in the present study.
(DOC)
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